Flagship Harbor Advisors, LLC Bei Gene, Ltd. Transaction History

Flagship Harbor Advisors, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 08, 2021	SELL	$221.31 - $316.61 $33,196 - $47,491	-150 Closed	0 $0
Q2 2020 Jul 31, 2020	SELL	$123.9 - $195.41 $30,975 - $48,852	-250 Reduced 62.5%	150 $28,000
Q1 2020 May 12, 2020	SELL	$121.84 - $173.19 $9,138 - $12,989	-75 Reduced 15.79%	400 $49,000
Q3 2019 Oct 22, 2019	BUY	$120.61 - $148.29 $57,289 - $70,437	475 New	475 $58,000

253

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $22.7B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Flagship Harbor Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Flagship Harbor Advisors, LLC with notifications on news.